Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Net Profit Margin
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Vertex Pharmaceuticals Inc., net profit margin, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands

Net Income (Loss)
The net income exhibited significant volatility throughout the observed period. Initially, the company experienced substantial losses from 2005 through 2010, with negative net income values deepening until 2010. A notable turnaround occurred in 2011, when net income turned positive, reaching 29,574 thousand US dollars. However, this improvement was short-lived, as losses resumed in 2012 and further intensified in 2013 and 2014. Beginning in 2015, net income again showed positive growth, peaking notably in 2018 at 2,096,896 thousand US dollars. Afterward, net income stayed positive and robust until 2023, despite some fluctuations. The year 2024 marked a sharp reversal to a loss of -535,600 thousand US dollars, indicating a sudden negative development in that final year.
Revenues
Revenue trends demonstrated a general upward trajectory over the entire period, albeit with some fluctuations in the early years. Revenues started relatively low in 2005 and varied modestly until 2010. From 2011 onwards, the company experienced strong growth in revenues, increasing steadily year-over-year. This growth accelerated significantly from around 2015, culminating in revenue reaching over 11 billion US dollars by 2024, showing a compound expansion of the company’s top line despite the occasional mid-period decreases, notably in 2009 and 2013-2014.
Net Profit Margin
The net profit margin mirrored the swings seen in net income, initially showing deep negative margins from 2005 through 2010, reaching extreme negative values close to -630% in 2009. Starting in 2011, margins improved and crossed into positive territory, although they returned to negative in 2012 and 2013. From 2014 onward, margins stabilized and improved markedly, peaking at 68.8% in 2018, reflecting a period of strong profitability relative to revenues. After 2018, margins remained healthy but declined somewhat, staying in the 30-37% range through 2023, before sharply dropping to a negative margin of -4.86% in 2024, consistent with the observed net income loss that year.
Overall Analysis
The financial performance reveals a company transitioning from prolonged losses toward sustained profitability beginning in 2011. Revenues grew substantially throughout the period, supporting improved profitability and net income results during the latter years. The spike in profitability around 2018 indicates a particularly strong operational or market position at that time. However, the return to losses and negative margins in 2024 suggests emerging challenges or one-off impacts that reversed the previous positive trend. Continuous expansion in revenues coupled with volatile profitability highlights the dynamic nature of the company’s financial environment, warranting further investigation into the causes behind the 2024 downturn.

Comparison to Competitors

Vertex Pharmaceuticals Inc., net profit margin, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Vertex Pharmaceuticals Inc., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)

Vertex Pharmaceuticals Inc., net profit margin, long-term trends, comparison to industry (health care)

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).